Novel Inhibitors of Checkpoint Kinase 1

K. Arrington,V. Dudkin

DOI: https://doi.org/10.1002/cmdc.200700131

IF: 3.54

2007-11-12

ChemMedChem

Abstract:To date, DNA-damaging chemotherapeutic agents constitute a basic tool set in the treatment of cancer. Whereas a number of such drugs have achieved widespread use, their shortcomings are well documented and include toxicity associated with lack of selectivity for tumors over normal proliferating cells, as well as efficacy limitations. Thus, widening the therapeutic window of DNA-damaging chemotherapies would lead to significant improvement in cancer care. Ideally, a dividing tumor cell would progress into mitosis after sustaining DNA damage inflicted by chemotherapy and subsequently undergo mitotic catastrophe and apoptosis. However, cells have the ability to halt the cell cycle in G1, G2, or S phases and pause to allow for DNA repair. Temporary arrest of the progression of the cell cycle therefore provides a survival mechanism for tumor cells and can be mediated through both p53 and Chk1 pathway activation. Whereas normal proliferating cells have an intact p53 pathway, it is compromised in many tumors, and for these Chk1-mediated G2/S arrest becomes a dominant defense mechanism from DNA-damaging chemotherapy. Inhibition of Chk1 in such p53-deficient tumor cells with damaged DNA would abrogate the cell-cycle arrest and force the progression into mitosis resulting in cell death, thus selectively sensitizing these tumor types to chemotherapy. Accordingly, combination therapy comprising a DNA-damaging agent with a Chk1 inhibitor will potentially have a significantly higher therapeutic index than chemotherapy alone. Such realizations have driven great interest in the discovery of selective inhibitors of Chk1 kinase with a number of pharmaceutical companies and academic research labs contributing to the effort. This minireview will focus on the challenges and recent progress achieved in this area from a medicinal chemistry perspective. In a majority of publications, inhibition of Chk1 enzymatic activity serves as a primary assay for compound screening. This can be followed by a number of experiments designed to evaluate functional activity in a cellular context, which typically measure effects of compound administration on either checkpoint abrogation or antiproliferative activity of a DNA-damaging agent. Cell cycle profile (FACS) analysis has been employed to observe changes in cell distribution from abrogation of checkpoint arrest and apoptosis following administration of a DNA damaging agent and Chk1 inhibitor. A similar observation is made in the checkpoint escape assay which utilizes an immunohistochemistry approach to measure the extent of mitotic marker expression. Antiproliferative effects of Chk1 inhibitors have been investigated with inhibition of colony formation or cell viability (for example, MTS) assays demonstrating sensitization of tumor cell lines to a DNA-damaging agent. Finally, measurement of Chk1 autophosphorylation provides a direct readout of a compound’s inhibitory activity at the cellular level. In recent years (2005–2007) both enzymatic and functional activity data have become available for novel Chk1 inhibitors belonging to a number of structurally distinct series. Among these promising series, the diaryl ureas, fusedpyrazoles, quinolinones, aminopyrimidines, and others, are described below.